U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C6H6N6O2
Molecular Weight 194.1508
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TEMOZOLOMIDE

SMILES

CN1N=NC2=C(N=CN2C1=O)C(N)=O

InChI

InChIKey=BPEGJWRSRHCHSN-UHFFFAOYSA-N
InChI=1S/C6H6N6O2/c1-11-6(14)12-2-8-3(4(7)13)5(12)9-10-11/h2H,1H3,(H2,7,13)

HIDE SMILES / InChI
Molecular Formula C6H6N6O2
Molecular Weight 194.1508
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://www.google.com/patents/WO2012027693A3 | https://www.ncbi.nlm.nih.gov/pubmed/24994771

NEO 212 is novel DNA alkylating agent exhibiting superior activity against breast cancer cells in vitro and intracranial triple-negative tumor growth in vivo. NEO212 is a conjugate of temozolomide (TMZ,) with the natural product perillyl alcohol (POH). NEO 212 causes DNA damage and cell death much more efficiently than TMZ because linkage with POH increased it's biological half-life and thus provided greater opportunity for placement of cytotoxic DNA lesions.

CNS Activity

CNS Active
4002
Curator's Comment: TMZ (TEMOZOLOMIDE) is 100% bioavailable when taken orally and, because of its small size and lipophilic properties, it is able to cross the blood-brain barrier. Concentrations in the central nervous system are approximately 30% of plasma concentrations. Once it has entered the central nervous system, TMZ can be spontaneously converted to the active metabolite. These pharmacologic properties make it an ideal agent for treating central nervous system malignancies.

Originator

Neonc Technologies
2
Curator's Comment: The story of temozolomide starts in the late 1970s in Birmingham, where Professor Stevens was leading a team of researchers at Aston University.

Approval Year

1999
175
Targets

Targets

Primary TargetPharmacologyConditionPotency
Crosslinking Agent
83
DNA
282
Target ID: CHEMBL2311221
Blocker
555
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8583
TEMODAR

Approved Use

Newly diagnosed glioblastoma multiforme (GBM) concomitantly with radiotherapy and then as maintenance treatment; Refractory anaplastic astrocytoma, patients who have experienced disease progression on a drug regimen containing nitrosourea and procarbazine

Launch Date

1999
Primary
Approved
8583
TEMODAR

Approved Use

Newly diagnosed glioblastoma multiforme (GBM) concomitantly with radiotherapy and then as maintenance treatment; Refractory anaplastic astrocytoma, patients who have experienced disease progression on a drug regimen containing nitrosourea and procarbazine

Launch Date

1999
Primary
Basic research
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
7.5 μg/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021029s031lbl.pdf
150 mg/m² single, oral
dose: 150 mg/m²
route of administration: Oral
experiment type: SINGLE
co-administered:
TEMOZOLOMIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
23.4 μg × h/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021029s031lbl.pdf
150 mg/m² single, oral
dose: 150 mg/m²
route of administration: Oral
experiment type: SINGLE
co-administered:
TEMOZOLOMIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1.89 h
Clinical Trial
https://clinicaltrials.gov/ct2/show/NCT02343081
200 mg/m^2 single, oral
dose: 200 mg/m^2
route of administration: oral
experiment type: single
co-administered:
TEMOZOLOMIDE plasma
Homo sapiens
1.87 h
Clinical Trial
https://clinicaltrials.gov/ct2/show/NCT02343081
200 mg/m^2 single, oral
dose: 200 mg/m^2
route of administration: oral
experiment type: single
co-administered:
TEMOZOLOMIDE plasma
Homo sapiens
1.8 h
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021029s031lbl.pdf
150 mg/m² single, oral
dose: 150 mg/m²
route of administration: Oral
experiment type: SINGLE
co-administered:
TEMOZOLOMIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
85%
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021029s031lbl.pdf
150 mg/m² single, oral
dose: 150 mg/m²
route of administration: Oral
experiment type: SINGLE
co-administered:
TEMOZOLOMIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
1000 mg/m2 1 times / 4 weeks multiple, oral
Highest studied dose
Dose: 1000 mg/m2, 1 times / 4 weeks
Route: oral
Route: multiple
Dose: 1000 mg/m2, 1 times / 4 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/14740784/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://pubmed.ncbi.nlm.nih.gov/14740784/
Other AEs: Neutropenia, Thrombocytopenia...
Other AEs:
Neutropenia (grade 4, 2 patients)
Thrombocytopenia (grade 4, 1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/14740784/
250 mg/m2 1 times / day multiple, oral
Highest studied dose
Dose: 250 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10576660/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://pubmed.ncbi.nlm.nih.gov/10576660/
DLT: Thrombocytopenia...
Other AEs: Anaemia, Neutropenia...
Dose limiting toxicities:
Thrombocytopenia (grade 4, 2 patients)
Other AEs:
Anaemia (grade 3, 1 patient)
Neutropenia (grade 3, 2 patients)
Sources:
https://pubmed.ncbi.nlm.nih.gov/10576660/
200 mg/m2 1 times / day multiple, oral
MTD
Dose: 200 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10576660/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://pubmed.ncbi.nlm.nih.gov/10576660/
Other AEs: Anaemia...
Other AEs:
Anaemia (grade 4, 1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/10576660/
750 mg/m2 1 times / 4 weeks multiple, oral
MTD
Dose: 750 mg/m2, 1 times / 4 weeks
Route: oral
Route: multiple
Dose: 750 mg/m2, 1 times / 4 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/14740784/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://pubmed.ncbi.nlm.nih.gov/14740784/
Other AEs: Neutropenia, Thrombocytopenia...
Other AEs:
Neutropenia (grade 4, 1 patient)
Thrombocytopenia (grade 3, 2 patients)
Sources:
https://pubmed.ncbi.nlm.nih.gov/14740784/
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Other AEs: Anorexia, Dizziness...
Other AEs:
Anorexia (all grades, 27%)
Dizziness (all grades, 5%)
Fatigue (all grades, 61%)
Headache (all grades, 23%)
Weakness (all grades, 7%)
Confusion (all grades, 5%)
Convulsions (all grades, 11%)
Memory impairment (all grades, 7%)
Vision blurred (all grades, 8%)
Allergic reaction (all grades, 3%)
Abdominal pain (all grades, 5%)
Constipation (all grades, 22%)
Diarrhea (all grades, 10%)
Nausea (all grades, 49%)
Stomatitis (all grades, 9%)
Vomiting (all grades, 29%)
Radiation injury NOS (all grades, 2%)
Arthralgia (all grades, 6%)
Thrombocytopenia (all grades, 8%)
Insomnia (all grades, 4%)
Coughing (all grades, 8%)
Dyspnea (all grades, 5%)
Alopecia (all grades, 55%)
Dry skin (all grades, 5%)
Erythema (all grades, 1%)
Pruritus (all grades, 5%)
Rash (all grades, 13%)
Taste perversion (all grades, 5%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Other AEs: Headache, Fatigue...
Other AEs:
Headache (all grades, 41%)
Fatigue (all grades, 34%)
Asthenia (all grades, 13%)
Fever (all grades, 13%)
Back pain (all grades, 8%)
Edema peripheral (all grades, 11%)
Convulsions (all grades, 23%)
Hemiparesis (all grades, 18%)
Dizziness (all grades, 12%)
Coordination abnormal (all grades, 11%)
Amnesia (all grades, 10%)
Insomnia (all grades, 10%)
Paresthesia (all grades, 9%)
Somnolence (all grades, 9%)
Paresis (all grades, 8%)
Urinary incontinence (all grades, 8%)
Ataxia (all grades, 8%)
Dysphasia (all grades, 7%)
Convulsions local (all grades, 6%)
Abnormal gait (all grades, 6%)
Confusion (all grades, 5%)
Adrenal hypercorticism (all grades, 8%)
Nausea (all grades, 53%)
Vomiting (all grades, 42%)
Constipation (all grades, 33%)
Diarrhea (all grades, 16%)
Abdominal pain (all grades, 9%)
Anorexia (all grades, 9%)
Weight increase (all grades, 5%)
Myalgia (all grades, 5%)
Anxiety (all grades, 7%)
Depression (all grades, 6%)
Breast pain female (all grades, 6%)
Infection viral (all grades, 11%)
Upper respiratory tract infection (all grades, 8%)
Pharyngitis (all grades, 8%)
Sinusitis (all grades, 6%)
Coughing (all grades, 5%)
Rash (all grades, 8%)
Pruritus (all grades, 8%)
Urinary tract infection (all grades, 8%)
Micturition frequency increased (all grades, 6%)
Diplopia (all grades, 5%)
Abnormal vision (all grades, 5%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
75 mg/m2 1 times / day multiple, oral
Recommended
Dose: 75 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Other AEs: Anorexia, Dizziness...
Other AEs:
Anorexia (all grades, 19%)
Dizziness (all grades, 4%)
Fatigue (all grades, 54%)
Headache (all grades, 19%)
Weakness (all grades, 3%)
Confusion (all grades, 4%)
Convulsions (all grades, 6%)
Memory impairment (all grades, 3%)
Vision blurred (all grades, 9%)
Allergic reaction (all grades, 5%)
Abdominal pain (all grades, 2%)
Constipation (all grades, 18%)
Diarrhea (all grades, 6%)
Nausea (all grades, 36%)
Stomatitis (all grades, 7%)
Vomiting (all grades, 20%)
Radiation injury NOS (all grades, 7%)
Arthralgia (all grades, 2%)
Thrombocytopenia (all grades, 4%)
Insomnia (all grades, 5%)
Coughing (all grades, 5%)
Dyspnea (all grades, 4%)
Alopecia (all grades, 69%)
Dry skin (all grades, 2%)
Erythema (all grades, 5%)
Pruritus (all grades, 4%)
Rash (all grades, 19%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
AEs

AEs

AESignificanceDosePopulation
Thrombocytopenia grade 4, 1 patient
1000 mg/m2 1 times / 4 weeks multiple, oral
Highest studied dose
Dose: 1000 mg/m2, 1 times / 4 weeks
Route: oral
Route: multiple
Dose: 1000 mg/m2, 1 times / 4 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/14740784/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://pubmed.ncbi.nlm.nih.gov/14740784/
Neutropenia grade 4, 2 patients
1000 mg/m2 1 times / 4 weeks multiple, oral
Highest studied dose
Dose: 1000 mg/m2, 1 times / 4 weeks
Route: oral
Route: multiple
Dose: 1000 mg/m2, 1 times / 4 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/14740784/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://pubmed.ncbi.nlm.nih.gov/14740784/
Anaemia grade 3, 1 patient
250 mg/m2 1 times / day multiple, oral
Highest studied dose
Dose: 250 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10576660/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://pubmed.ncbi.nlm.nih.gov/10576660/
Neutropenia grade 3, 2 patients
250 mg/m2 1 times / day multiple, oral
Highest studied dose
Dose: 250 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10576660/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://pubmed.ncbi.nlm.nih.gov/10576660/
Thrombocytopenia grade 4, 2 patients
DLT
250 mg/m2 1 times / day multiple, oral
Highest studied dose
Dose: 250 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10576660/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://pubmed.ncbi.nlm.nih.gov/10576660/
Anaemia grade 4, 1 patient
200 mg/m2 1 times / day multiple, oral
MTD
Dose: 200 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10576660/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://pubmed.ncbi.nlm.nih.gov/10576660/
Thrombocytopenia grade 3, 2 patients
750 mg/m2 1 times / 4 weeks multiple, oral
MTD
Dose: 750 mg/m2, 1 times / 4 weeks
Route: oral
Route: multiple
Dose: 750 mg/m2, 1 times / 4 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/14740784/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://pubmed.ncbi.nlm.nih.gov/14740784/
Neutropenia grade 4, 1 patient
750 mg/m2 1 times / 4 weeks multiple, oral
MTD
Dose: 750 mg/m2, 1 times / 4 weeks
Route: oral
Route: multiple
Dose: 750 mg/m2, 1 times / 4 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/14740784/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://pubmed.ncbi.nlm.nih.gov/14740784/
Erythema all grades, 1%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Diarrhea all grades, 10%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Convulsions all grades, 11%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Rash all grades, 13%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Radiation injury NOS all grades, 2%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Constipation all grades, 22%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Headache all grades, 23%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Anorexia all grades, 27%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Vomiting all grades, 29%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Allergic reaction all grades, 3%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Insomnia all grades, 4%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Nausea all grades, 49%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Abdominal pain all grades, 5%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Confusion all grades, 5%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Dizziness all grades, 5%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Dry skin all grades, 5%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Dyspnea all grades, 5%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Pruritus all grades, 5%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Taste perversion all grades, 5%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Alopecia all grades, 55%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Arthralgia all grades, 6%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Fatigue all grades, 61%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Memory impairment all grades, 7%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Weakness all grades, 7%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Coughing all grades, 8%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Thrombocytopenia all grades, 8%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Vision blurred all grades, 8%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Stomatitis all grades, 9%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Amnesia all grades, 10%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Insomnia all grades, 10%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Coordination abnormal all grades, 11%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Edema peripheral all grades, 11%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Infection viral all grades, 11%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Dizziness all grades, 12%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Asthenia all grades, 13%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Fever all grades, 13%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Diarrhea all grades, 16%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Hemiparesis all grades, 18%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Convulsions all grades, 23%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Constipation all grades, 33%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Fatigue all grades, 34%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Headache all grades, 41%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Vomiting all grades, 42%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Abnormal vision all grades, 5%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Confusion all grades, 5%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Coughing all grades, 5%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Diplopia all grades, 5%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Myalgia all grades, 5%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Weight increase all grades, 5%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Nausea all grades, 53%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Abnormal gait all grades, 6%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Breast pain female all grades, 6%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Convulsions local all grades, 6%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Depression all grades, 6%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Micturition frequency increased all grades, 6%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Sinusitis all grades, 6%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Anxiety all grades, 7%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Dysphasia all grades, 7%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Adrenal hypercorticism all grades, 8%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Ataxia all grades, 8%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Back pain all grades, 8%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Paresis all grades, 8%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Pharyngitis all grades, 8%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Pruritus all grades, 8%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Rash all grades, 8%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Upper respiratory tract infection all grades, 8%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Urinary incontinence all grades, 8%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Urinary tract infection all grades, 8%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Abdominal pain all grades, 9%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Anorexia all grades, 9%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Paresthesia all grades, 9%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Somnolence all grades, 9%
150 mg/m2 1 times / day multiple, oral
Recommended
Dose: 150 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Constipation all grades, 18%
75 mg/m2 1 times / day multiple, oral
Recommended
Dose: 75 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Anorexia all grades, 19%
75 mg/m2 1 times / day multiple, oral
Recommended
Dose: 75 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Headache all grades, 19%
75 mg/m2 1 times / day multiple, oral
Recommended
Dose: 75 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Rash all grades, 19%
75 mg/m2 1 times / day multiple, oral
Recommended
Dose: 75 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Abdominal pain all grades, 2%
75 mg/m2 1 times / day multiple, oral
Recommended
Dose: 75 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Arthralgia all grades, 2%
75 mg/m2 1 times / day multiple, oral
Recommended
Dose: 75 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Dry skin all grades, 2%
75 mg/m2 1 times / day multiple, oral
Recommended
Dose: 75 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Vomiting all grades, 20%
75 mg/m2 1 times / day multiple, oral
Recommended
Dose: 75 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Memory impairment all grades, 3%
75 mg/m2 1 times / day multiple, oral
Recommended
Dose: 75 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Weakness all grades, 3%
75 mg/m2 1 times / day multiple, oral
Recommended
Dose: 75 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Nausea all grades, 36%
75 mg/m2 1 times / day multiple, oral
Recommended
Dose: 75 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Confusion all grades, 4%
75 mg/m2 1 times / day multiple, oral
Recommended
Dose: 75 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Dizziness all grades, 4%
75 mg/m2 1 times / day multiple, oral
Recommended
Dose: 75 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Dyspnea all grades, 4%
75 mg/m2 1 times / day multiple, oral
Recommended
Dose: 75 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Pruritus all grades, 4%
75 mg/m2 1 times / day multiple, oral
Recommended
Dose: 75 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Thrombocytopenia all grades, 4%
75 mg/m2 1 times / day multiple, oral
Recommended
Dose: 75 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Allergic reaction all grades, 5%
75 mg/m2 1 times / day multiple, oral
Recommended
Dose: 75 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Coughing all grades, 5%
75 mg/m2 1 times / day multiple, oral
Recommended
Dose: 75 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Erythema all grades, 5%
75 mg/m2 1 times / day multiple, oral
Recommended
Dose: 75 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Insomnia all grades, 5%
75 mg/m2 1 times / day multiple, oral
Recommended
Dose: 75 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Fatigue all grades, 54%
75 mg/m2 1 times / day multiple, oral
Recommended
Dose: 75 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Convulsions all grades, 6%
75 mg/m2 1 times / day multiple, oral
Recommended
Dose: 75 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Diarrhea all grades, 6%
75 mg/m2 1 times / day multiple, oral
Recommended
Dose: 75 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Alopecia all grades, 69%
75 mg/m2 1 times / day multiple, oral
Recommended
Dose: 75 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Radiation injury NOS all grades, 7%
75 mg/m2 1 times / day multiple, oral
Recommended
Dose: 75 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Stomatitis all grades, 7%
75 mg/m2 1 times / day multiple, oral
Recommended
Dose: 75 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Vision blurred all grades, 9%
75 mg/m2 1 times / day multiple, oral
Recommended
Dose: 75 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:72564
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:72564
ChemicalBook
CB2708199
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB2708199
eMolecules
745657
https://www.emolecules.com/cgi-bin/more?vid=745657
MolPort
MolPort-003-850-406
https://www.molport.com/shop/molecule-link/MolPort-003-850-406
Selleck Chemicals
Methazolastone
http://www.selleckchem.com/products/Methazolastone.html
ZINC
ZINC000001482184
http://zinc15.docking.org/substances/ZINC000001482184
PubMed

PubMed

TitleDatePubMed
Therapeutic management of refractory or relapsed primary central nervous system lymphomas.
2001
Adults with newly diagnosed high-grade gliomas.
2001 Dec
Low-grade gliomas.
2001 Dec
Brain metastases from fallopian tube carcinoma responsive to intra-arterial carboplatin and intravenous etoposide: a case report.
2001 Dec
Role of cytochrome P450 isoenzymes in metabolism of O(6)-benzylguanine: implications for dacarbazine activation.
2001 Dec
Temozolomide (Temodar).
2001 Jan-Feb
Controversies in the management of brain metastases: the role of chemotherapy.
2001 Jan-Mar
A phase II trial of temozolomide for patients with recurrent or progressive brain metastases.
2001 Jul
Temozolomide: a novel oral alkylating agent.
2001 Jun
Metastatic melanoma.
2001 Jun
Possible efficacy of temozolomide in a patient with gliomatosis cerebri.
2001 Nov 27
New perspectives for the diagnosis and treatment of oligodendroglioma.
2001 Oct
Treatment of metastatic melanoma in the brain with temozolomide and thalidomide.
2001 Oct
Targeting DNA mismatch repair for radiosensitization.
2001 Oct
Current and future developments in the use of temozolomide for the treatment of brain tumours.
2001 Sep
Temozolomide in patients with glioblastoma at second relapse after first line nitrosourea-procarbazine failure: a phase II study.
2002
Concomitant radiotherapy and metronomic temozolomide in pediatric high-risk brain tumors.
2002
Pharmacokinetic considerations of oral chemotherapy in elderly patients with cancer.
2002
Synthesis and antibacterial activity of dual-action agents of a beta-lactam antibiotic with cytotoxic agent mitozolomide or temozolomide.
2002 Apr
A phase II EORTC study of temozolomide in patients with malignant pleural mesothelioma.
2002 Apr
Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group.
2002 Apr
Effect of temozolomide on central nervous system relapse in patients with advanced melanoma.
2002 Apr
Photodynamic therapy of DNA mismatch repair-deficient and -proficient tumour cells.
2002 Apr 8
Cancer Research UK procedures in manufacture and toxicology of radiotracers intended for pre-phase I positron emission tomography studies in cancer patients.
2002 Apr 8
A phase II trial of oral temozolomide in patients with metastatic renal cell cancer.
2002 Aug
Multifaceted resistance of gliomas to temozolomide.
2002 Aug
Phase I study of temozolomide in relapsed/refractory acute leukemia.
2002 Aug 1
Effect of O6-(4-bromothenyl)guanine on different temozolomide schedules in a human melanoma xenograft model.
2002 Aug 10
A rapid and systematic review of the effectiveness of temozolomide for the treatment of recurrent malignant glioma.
2002 Feb 12
NICE verdict on Temozolomide: where next?
2002 Feb 12
A phase II study of extended low-dose temozolomide in recurrent malignant gliomas.
2002 Jan
Temozolomide in combination with docetaxel in patients with advanced melanoma: a phase II study of the Hellenic Cooperative Oncology Group.
2002 Jan 15
Combined radiotherapy and temozolomide in patients with recurrent high grade glioma.
2002 Jan-Feb
Temozolomide in glioblastoma multiforme of the elderly.
2002 Jan-Feb
Temozolomide-induced flare in high-grade gliomas: a new clinical entity.
2002 Jul
Pharmacological strategies to increase the antitumor activity of methylating agents.
2002 Jul
Promising survival and concomitant radiation plus temozolomide followed by adjuvant temozolomide.
2002 Jul 15
Treatment of newly diagnosed glioblastoma multiforme.
2002 Jul 15
Temozolomide plus thalidomide in patients with advanced melanoma: results of a dose-finding trial.
2002 Jun 1
Chemotherapy-induced O(6)-benzylguanine-resistant alkyltransferase mutations in mismatch-deficient colon cancer.
2002 Jun 1
Heterogeneity of O6-alkylguanine DNA-alkyltransferase expression in human breast tumours.
2002 Jun 5
Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme.
2002 Mar 1
Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide.
2002 Mar 1
Prevention of irradiation-induced glioma cell invasion by temozolomide involves caspase 3 activity and cleavage of focal adhesion kinase.
2002 Mar 15
Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site.
2002 Mar 15
Temozolomide as second-line chemotherapy for relapsed gliomas.
2002 May
Gateways to clinical trials.
2002 May
Clinical relevance of MGMT in the treatment of cancer.
2002 May 1
[Treatment of recidive malignant gliomas with temozolomide].
2002 May 26
First-line therapy with temozolomide induces regression of primary CNS lymphoma.
2002 May 28
Patents

Patents

07087751
3
07446209
3
JP2004534046A
7
JP2007169300A
2
JP2009526755A
475
JP2011525180A
180
JP4054057B2
2
JP4701159B2
91
JP4851943B2
62
WO2012027693
2

Sample Use Guides

In Vivo Use Guide
Curator's Comment: Dosage of TEMODAR must be adjusted according to nadir neutrophil and platelet counts in the previous cycle and the neutrophil and platelet counts at the time of initiating the next cycle. For TEMODAR dosage calculations based on body surface area (BSA). Is used: 5 mg, 20 mg, 100 mg, 140 mg, 180 mg, and 250 mg capsules and 100 mg powder for injection
intravenous infusion over 90 minutes is the same as the dose for the oral capsule formulation. Bioequivalence has been established only when TEMODAR for Injection was given over 90 minutes.
Route of Administration: Intravenous
In Vitro Use Guide
Grade IV glioma cell lines SHG44 and U251 cells were treated with 100 µmol/LT EMOZOLOMIDE (TMZ)
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:05:03 GMT 2025
Edited
by admin
on Mon Mar 31 18:05:03 GMT 2025
Record UNII
YF1K15M17Y
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TEMOZOLOMIDE
EMA EPAR   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP-RS   VANDF   WHO-DD  
INN   USAN  
Official Name English
TEMODAL
Preferred Name English
temozolomide [INN]
Common Name English
MK-7365
Common Name English
NSC-362856
Code English
TEMOZOLOMIDE [EMA EPAR]
Common Name English
CCRG-81045
Code English
M&B-39831
Code English
M-39831
Code English
TEMOZOLOMIDE [EP MONOGRAPH]
Common Name English
METHAZOLASTONE
Common Name English
SCH 52365
Code English
TEMOZOLOMIDE [JAN]
Common Name English
TEMOZOLOMIDE [USAN]
Common Name English
TEMOZOLOMIDE [ORANGE BOOK]
Common Name English
SCH-52365
Code English
3,4-Dihydro-3-methyl-4-oxoimidazo[5,1-d]-as-tetrazine-8-carboxamide
Common Name English
TEMOZOLOMIDE [USP MONOGRAPH]
Common Name English
IMIDAZO(5,1-D)-1,2,3,5-TETRAZINE-8-CARBOXAMIDE, 3,4-DIHYDRO-3-METHYL-4-OXO-
Systematic Name English
TEMOZOLOMIDE [USP-RS]
Common Name English
TEMOZOLOMIDE [MART.]
Common Name English
TEMOZOLOMIDE [MI]
Common Name English
Temozolomide [WHO-DD]
Common Name English
M&B 39831
Code English
TEMODAR
Brand Name English
TEMOZOLOMIDE [VANDF]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C902
Created by admin on Mon Mar 31 18:05:03 GMT 2025 , Edited by admin on Mon Mar 31 18:05:03 GMT 2025
NDF-RT N0000175558
Created by admin on Mon Mar 31 18:05:03 GMT 2025 , Edited by admin on Mon Mar 31 18:05:03 GMT 2025
WHO-ATC L01AX03
Created by admin on Mon Mar 31 18:05:03 GMT 2025 , Edited by admin on Mon Mar 31 18:05:03 GMT 2025
NDF-RT N0000000236
Created by admin on Mon Mar 31 18:05:03 GMT 2025 , Edited by admin on Mon Mar 31 18:05:03 GMT 2025
FDA ORPHAN DRUG 116798
Created by admin on Mon Mar 31 18:05:03 GMT 2025 , Edited by admin on Mon Mar 31 18:05:03 GMT 2025
EMA ASSESSMENT REPORTS TEMOZOLOMIDE SUN (AUTHORIZED: GLIOMA, GLIOBLASTOMA)
Created by admin on Mon Mar 31 18:05:03 GMT 2025 , Edited by admin on Mon Mar 31 18:05:03 GMT 2025
FDA ORPHAN DRUG 895222
Created by admin on Mon Mar 31 18:05:03 GMT 2025 , Edited by admin on Mon Mar 31 18:05:03 GMT 2025
EMA ASSESSMENT REPORTS TEMOZOLOMIDE TEVA (AUTHORIZED: GLIOMA, GLIOBLASTOMA)
Created by admin on Mon Mar 31 18:05:03 GMT 2025 , Edited by admin on Mon Mar 31 18:05:03 GMT 2025
EMA ASSESSMENT REPORTS TEMOZOLOMIDE SANDOZ (AUTHORIZED: GLIOMA, GLIOBLASTOMA)
Created by admin on Mon Mar 31 18:05:03 GMT 2025 , Edited by admin on Mon Mar 31 18:05:03 GMT 2025
EMA ASSESSMENT REPORTS TEMOZOLOMIDE HEXAL (AUTHORIZED: GLIOMA, GLIOBLASTOMA)
Created by admin on Mon Mar 31 18:05:03 GMT 2025 , Edited by admin on Mon Mar 31 18:05:03 GMT 2025
FDA ORPHAN DRUG 193904
Created by admin on Mon Mar 31 18:05:03 GMT 2025 , Edited by admin on Mon Mar 31 18:05:03 GMT 2025
WHO-VATC QL01AX03
Created by admin on Mon Mar 31 18:05:03 GMT 2025 , Edited by admin on Mon Mar 31 18:05:03 GMT 2025
EMA ASSESSMENT REPORTS TEMOMEDAC (AUTHORIZED: GLIOMA, GLIOBLASTOMA)
Created by admin on Mon Mar 31 18:05:03 GMT 2025 , Edited by admin on Mon Mar 31 18:05:03 GMT 2025
FDA ORPHAN DRUG 453314
Created by admin on Mon Mar 31 18:05:03 GMT 2025 , Edited by admin on Mon Mar 31 18:05:03 GMT 2025
EU-Orphan Drug EU/3/16/1733
Created by admin on Mon Mar 31 18:05:03 GMT 2025 , Edited by admin on Mon Mar 31 18:05:03 GMT 2025
FDA ORPHAN DRUG 497215
Created by admin on Mon Mar 31 18:05:03 GMT 2025 , Edited by admin on Mon Mar 31 18:05:03 GMT 2025
EMA ASSESSMENT REPORTS TEMODAL (AUTHORIZED: GLIOMA, GLIOBLASTOMA)
Created by admin on Mon Mar 31 18:05:03 GMT 2025 , Edited by admin on Mon Mar 31 18:05:03 GMT 2025
FDA ORPHAN DRUG 698519
Created by admin on Mon Mar 31 18:05:03 GMT 2025 , Edited by admin on Mon Mar 31 18:05:03 GMT 2025
LIVERTOX NBK548816
Created by admin on Mon Mar 31 18:05:03 GMT 2025 , Edited by admin on Mon Mar 31 18:05:03 GMT 2025
EMA ASSESSMENT REPORTS TEMOZOLOMIDE ACCORD (AUTHORIZED: GLIOMA, GLIOBLASTOMA
Created by admin on Mon Mar 31 18:05:03 GMT 2025 , Edited by admin on Mon Mar 31 18:05:03 GMT 2025
FDA ORPHAN DRUG 117198
Created by admin on Mon Mar 31 18:05:03 GMT 2025 , Edited by admin on Mon Mar 31 18:05:03 GMT 2025
Code System Code Type Description
EPA CompTox
DTXSID5043714
Created by admin on Mon Mar 31 18:05:03 GMT 2025 , Edited by admin on Mon Mar 31 18:05:03 GMT 2025
PRIMARY
MESH
C047246
Created by admin on Mon Mar 31 18:05:03 GMT 2025 , Edited by admin on Mon Mar 31 18:05:03 GMT 2025
PRIMARY
RXCUI
37776
Created by admin on Mon Mar 31 18:05:03 GMT 2025 , Edited by admin on Mon Mar 31 18:05:03 GMT 2025
PRIMARY RxNorm
CAS
85622-93-1
Created by admin on Mon Mar 31 18:05:03 GMT 2025 , Edited by admin on Mon Mar 31 18:05:03 GMT 2025
PRIMARY
USAN
LL-53
Created by admin on Mon Mar 31 18:05:03 GMT 2025 , Edited by admin on Mon Mar 31 18:05:03 GMT 2025
PRIMARY
RS_ITEM_NUM
1643543
Created by admin on Mon Mar 31 18:05:03 GMT 2025 , Edited by admin on Mon Mar 31 18:05:03 GMT 2025
PRIMARY
EVMPD
SUB10889MIG
Created by admin on Mon Mar 31 18:05:03 GMT 2025 , Edited by admin on Mon Mar 31 18:05:03 GMT 2025
PRIMARY
ChEMBL
CHEMBL810
Created by admin on Mon Mar 31 18:05:03 GMT 2025 , Edited by admin on Mon Mar 31 18:05:03 GMT 2025
PRIMARY
DRUG CENTRAL
2589
Created by admin on Mon Mar 31 18:05:03 GMT 2025 , Edited by admin on Mon Mar 31 18:05:03 GMT 2025
PRIMARY
LACTMED
Temozolamide
Created by admin on Mon Mar 31 18:05:03 GMT 2025 , Edited by admin on Mon Mar 31 18:05:03 GMT 2025
PRIMARY
FDA UNII
YF1K15M17Y
Created by admin on Mon Mar 31 18:05:03 GMT 2025 , Edited by admin on Mon Mar 31 18:05:03 GMT 2025
PRIMARY
INN
6027
Created by admin on Mon Mar 31 18:05:03 GMT 2025 , Edited by admin on Mon Mar 31 18:05:03 GMT 2025
PRIMARY
CHEBI
72564
Created by admin on Mon Mar 31 18:05:03 GMT 2025 , Edited by admin on Mon Mar 31 18:05:03 GMT 2025
PRIMARY
MERCK INDEX
m10552
Created by admin on Mon Mar 31 18:05:03 GMT 2025 , Edited by admin on Mon Mar 31 18:05:03 GMT 2025
PRIMARY Merck Index
WIKIPEDIA
TEMOZOLOMIDE
Created by admin on Mon Mar 31 18:05:03 GMT 2025 , Edited by admin on Mon Mar 31 18:05:03 GMT 2025
PRIMARY
PUBCHEM
5394
Created by admin on Mon Mar 31 18:05:03 GMT 2025 , Edited by admin on Mon Mar 31 18:05:03 GMT 2025
PRIMARY
DRUG BANK
DB00853
Created by admin on Mon Mar 31 18:05:03 GMT 2025 , Edited by admin on Mon Mar 31 18:05:03 GMT 2025
PRIMARY
SMS_ID
100000089638
Created by admin on Mon Mar 31 18:05:03 GMT 2025 , Edited by admin on Mon Mar 31 18:05:03 GMT 2025
PRIMARY
DAILYMED
YF1K15M17Y
Created by admin on Mon Mar 31 18:05:03 GMT 2025 , Edited by admin on Mon Mar 31 18:05:03 GMT 2025
PRIMARY
NSC
362856
Created by admin on Mon Mar 31 18:05:03 GMT 2025 , Edited by admin on Mon Mar 31 18:05:03 GMT 2025
PRIMARY
IUPHAR
7301
Created by admin on Mon Mar 31 18:05:03 GMT 2025 , Edited by admin on Mon Mar 31 18:05:03 GMT 2025
PRIMARY
NCI_THESAURUS
C1244
Created by admin on Mon Mar 31 18:05:03 GMT 2025 , Edited by admin on Mon Mar 31 18:05:03 GMT 2025
PRIMARY
Related Record Type Details
Structure of TEMOZOLOMIDE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
Structure of LOMEGUATRIB
ACTIVATOR -> TARGET
Potentiates theh activity of drugs that inhibit mismatched repair.
Related Record Type Details
Structure of METHYLHYDRAZINE
PRODRUG -> METABOLITE ACTIVE
Structure of MTIC
METABOLITE -> PARENT
URINE
Structure of 4-AMINO-5-IMIDAZOLE CARBOXAMIDE
METABOLITE -> PARENT
Related Record Type Details
Structure of 3-METHYL-4-OXO-3,4-DIHYDROIMIDAZO(5,1-D)(1,2,3,5)TETRAZINE-8-CARBONITRILE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of 2-AZAHYPOXANTHINE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of TEMOZOLOMIDE ACID
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of TEMOZOLOMIDE ACID
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of 4-AMINO-5-IMIDAZOLE CARBOXAMIDE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of 3-METHYL-4-OXO-3,4-DIHYDROIMIDAZO(5,1-D)(1,2,3,5)TETRAZINE-8-CARBONITRILE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 4-AMINO-5-IMIDAZOLE CARBOXAMIDE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 5-DIAZOIMIDAZOLE-4-CARBOXAMIDE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of 5-DIAZOIMIDAZOLE-4-CARBOXAMIDE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 2-AZAHYPOXANTHINE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
Structure of TEMOZOLOMIDE
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966